The most impactful development was the rapid success of Moderna's COVID-19 vaccine, Spikevax, which witnessed massive demand during the pandemic. Starting in early 2021, regulatory approvals from ...

Moderna collected $3.1 billion in 2024 Spikevax sales and $25 million from its newer mRESVIA. At its peak in 2022, Spikevax brought in $18.4 billion for the company.

In December 2020, both Moderna's Spikevax and Pfizer / BioNTech's Comirnaty COVID vaccines received emergency use authorization (“EUA”) in the US. Both used a pioneering new mechanism of ...

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna earned $3.2 billion from its vaccine Spikevax, according to ...

In its fourth quarter of 2025, Moderna reported $923 million in Spikevax sales, comprised of $244 million in the United States and $679 million internationally. Spikevax generated $3.1 billion in ...

The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market. This is very significant since most of the insider trades have been sales for the past year.

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever received at the company. The 16.4% increase—at grant value—came ...